STAT+: The panel was supposed to improve efficiency at the NIH. It hasn’t even met for 7 years
WASHINGTON — An oversight board tasked with making the National Institutes of Health more efficient…
Category: STAT+
STAT+: From burst bubble to medical marvel: How lipid nanoparticles became the future of gene therapy
Paddy Doherty leaned back in the narrow hospital bed and watched a bag of clear…
STAT+: Covid shots made Moderna biotech’s biggest star, but what now?
What does a breakout company like Moderna do for an encore? More than a decade…
STAT+: Pharmalittle: FDA restricts access to J&J Covid-19 vaccine; Novartis halts production of two cancer drugs over quality issues
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Omicron squeezed hospitals more than health insurers in the first quarter
The beginning of 2022 was kinder to health insurers than it was to hospitals. Many…
STAT+: Novartis suspends production of two cancer therapies over potential quality issues
Due to manufacturing issues, Novartis has voluntarily suspended production of two therapies that use nuclear…
STAT+: Cerebral, under intense scrutiny, is ‘actively adjusting’ strategy on ADHD ads
Amid intense scrutiny of its prescribing practices, the online mental health company Cerebral launched a…
STAT+: Pharmalittle: Abortion pill demand may rise if Roe v Wade is overturned; U.S. lawmakers move toward revamping accelerated approval
Top of the morning to you. Another deliciously shiny day is unfolding over the Pharmalot…
STAT+: Illumina, maker of a key tool for drug discovery, to try making new drugs itself
DNA sequencing giant Illumina announced Thursday that it would enter the field of drug discovery,…
STAT+: Congress moves toward reforming FDA accelerated approvals, but with pharma-friendly concessions
WASHINGTON — House lawmakers are moving a little closer toward cracking down on drug makers…
STAT+: Researchers describe the human element in the alchemy behind the Moderna vaccine and other new medicines
Veteran vaccine developer Jacqueline Miller joined Moderna in May 2020, at the height of the…
STAT+: Race is often overlooked in key clinical trial data used to win new drug approvals in Europe
Just two-thirds of the pivotal clinical trials that were used to win prescription drug approvals…
STAT+: FDA warns Miami University contract testing lab over falsified data, poor quality control
A contract testing laboratory run by Miami University was scolded by the U.S. Food and…
STAT+: Pharmalittle: Biogen is perilously poised for the future; WTO advances controversial Covid-vaccine patent waiver
Top of the morning to you. The middle of the week is upon us and,…
STAT+: Gates Foundation CEO has ‘zero expectation’ that Melinda French Gates will step down as co-chair after divorce
LOS ANGELES — In the most extensive public comments about the stewardship of the Bill…
STAT+: Biogen, fresh off major decisions on CEO and Aduhelm, faces next hurdles
Biogen, a stalwart of the global drug industry for the past four decades, is perilously…
STAT+: A compromise on patent waivers for Covid-19 vaccines takes a key step at the WTO
A controversial proposal before the World Trade Organization to waive patent rights for Covid-19 vaccines…
STAT+: Pharmalittle: Biogen CEO exits amid Aduhelm failures; FDA eschews its own outside expert panels
Rise and shine, everyone, another very busy day awaits. Even so, there is nothing like…
STAT+: Biogen to replace CEO as it ‘substantially’ curbs spending on its Alzheimer’s drug
Biogen is replacing CEO Michel Vounatsos, the company said Tuesday, ending a five-year tenure in…
STAT+: Five of Congress’ 10 biggest health earmarks went to Missouri clinics and universities
WASHINGTON — Hospitals, health clinics, and medical schools across the country had hoped to cash…
STAT+: Early cancer-detection market heats up as Guardant Health launches colon cancer test
Bay Area biotech Guardant Health announced the commercial launch of its early-detection colon cancer test…
STAT+: Is the FDA taking advice from its expert panels? A new analysis points to inconsistencies in the process
For decades, the U.S. Food and Drug Administration has relied on outside expert panels for…
.jpg)
STAT+: UnitedHealthcare restricts coverage of Aduhelm, following Medicare
UnitedHealthcare is restricting insurance coverage of Aduhelm across all of its health plans, saying the…
STAT+: U.N. committee urges wealthy nations to honor human rights conventions, widen access to Covid vaccines
A United Nations committee urged wealthy nations to support a proposal before the World Trade…
STAT+: FDA suspends early study of Vertex stem-cell therapy for type 1 diabetes
Vertex Pharmaceuticals said Monday that the Food and Drug Administration had suspended an early-stage clinical…
STAT+: Pharmalittle: FDA declines to approve two more drugs tested in China; Pfizer Covid pill fails to prevent infection in household members
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Despite biotech slump, veterans of SVB and KKR launch investment firm
Two of the top health care investors at the investment bank SVB Securities and the…
STAT+: Meet the lawmakers and lobbyists who want to bring health tech into the home
Years into the pandemic’s almost overnight transition to virtual care, providers and health plans are…
STAT+: An algorithm that analyzes Apple Watch data shows early promise in detecting heart problems
Mayo Clinic is developing an algorithm capable of detecting a weak heart pump from electrocardiograms…
STAT+: U.S. Trade Rep report sparks concern that a new clash may occur over clinical trial transparency
A recent Biden administration report on “significant” foreign barriers to U.S. exports suggests that a…
STAT+: Biogen board slashes CEO’s bonus as Aduhelm sales and overall business struggle
Biogen CEO Michel Vounatsos had his bonus cut in half to “hold him accountable for…
STAT+: Pharmalittle: Investors reject proposals for Covid vaccine makers to share know-how; CMS head says Alzheimer’s drug decision is rare
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Startups are turning to a century-old technology to fuel a resurgence in neuro drug development
Biotechs are used to turning to genetics as guideposts in developing new medications. Now, a…
STAT+: Medicare’s Brooks-LaSure expects restrictions on accelerated approval drugs, like those for Aduhelm, to be ‘very rare’
AUSTIN, Texas – Chiquita Brooks-LaSure, the head of Medicare, said on Thursday that the agency…
STAT+: The revolving door swings again as Lupin hires an FDA official who oversaw problems at a key plant
The revolving door between the U.S. Food and Drug Administration and the pharmaceutical industry turned…
STAT+: California fines an OptumRx pharmacy for jeopardizing patient health. Is that enough?
The California Board of Pharmacy fined OptumRx, one of the largest pharmacy benefit managers in…
STAT+: With new diabetes drug data, Eli Lilly is taking aim at obesity
Eli Lilly released new data Thursday showing that an injectable diabetes drug it is developing,…
STAT+: Pharmalittle: Amgen faces $7B IRS back-tax bill and fine; McKinsey exec apologizes for opioid work during hearing
Rise and shine. Another busy day is on the way. Indeed, the official to-do list…
STAT+: Tough questions, few answers: The FDA wrestles with its approach to AI in medicine
It was a brave thing for the Food and Drug Administration to do. Earlier this…
STAT+: A company developing a human blood substitute attempts a comeback, but IPO plans look dicey
Biopure, the disgraced developer of a failed human blood substitute, is attempting a comeback. It’s…
STAT+: Hospital giant Tenet sues OSHA for attempting to inspect hospital under Covid-19 worker safety rule
A large, investor-owned hospital chain is suing a federal agency, arguing workplace health officials don’t…
STAT+: Pharmalittle: J&J sues wholesalers and a pharmacy over fake HIV meds; Rite Aid to pay $123 million to Humana for inflating drug prices
Top of the morning to you. Another busy day is unfolding here on the Pharmalot…
STAT+: Usual and customary? Rite Aid ordered to pay Humana $123 million for inflating pharmacy claims
Rite Aid was ordered by an arbitrator to pay nearly $123 million to Humana, one…
STAT+: Pharmalittle: White House announces Covid-pill push; ‘right-to-try’ think tank is back with a new law
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right…
STAT+: Biofourmis raises $300 million as it looks to drive adoption of remote care
Biofourmis has spent years trying to figure out how to help care for patients with…
STAT+: Right to try 2.0: Advocates want to reduce oversight of ‘n of 1’ therapies
WASHINGTON — The libertarian think tank behind the federal “right-to-try” law is back at it…
STAT+: Thanks to Covid-19, pharma’s reputation improved among patient groups. But can it last?
Thanks to its response to the Covid-19 pandemic, the pharmaceutical industry has greatly improved its…
STAT+: Biden is urged to pursue march-in rights for a pricey cancer drug after NIH delays a petition review
Citing arguments by more than two dozen legal experts, Sen. Elizabeth Warren (D-Mass.) is urging…
STAT+: One in four pharma status reports on follow-up trials are late or aren’t filed
Drug companies failed to submit 11% of status reports for clinical trials they were required…
STAT+: Pharma R&D payments to European researchers are like ‘dark money’
Due to inadequate disclosure policies, drug company payments to European researchers and institutions for R&D…